Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP14.05 - Small Cell Lung Cancer and Neuro-endocrine Tumors - RW/SOC
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Small Cell Lung Cancer and Neuro-endocrine Tumors - RW/SOC
-
+
EP14.05-023 - Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States
Presenter: Xue Wang- Abstract
Loading...
-
+
EP16.03 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
-
+
EP16.03-024 - Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A
Presenter: Mark Klein- Abstract
Loading...
-
+
MA06 - Resectable and Unresectable Locally Advanced Lung Cancer
- 12:15 - 13:15
- 8/08/2022
- Location: Lehar 1
- Not for CME Credit
- Type: Mini Oral
- Track: Locally Advanced Non-small Cell Lung Cancer
- Moderators:Saulius Cicenas, Celine Mascaux
-
+
MA06.05 - Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC
12:27 - 12:32 | Presenter: Greg Andrew Durm
- Abstract
Loading...
